Are Fibrin-Related Markers Useful for the Diagnosis of Thrombosis?

 

 Buy Article Permissions and Reprints

ABSTRACT

Fibrin-related markers (FRMs), such as fibrin and fibrinogen degradation products (FDPs), D-dimer, and soluble fibrin (SF), are considered to be useful for the diagnosis of thrombosis. However, the evidence for the making of a diagnosis of thrombosis based on FRMs is, as yet, not fully established. Levels of FRMs are significantly elevated in patients with thrombosis, such as deep vein thrombosis, disseminated intravascular coagulation, and so on. In Japan, the D-dimer assay test result might be 2-fold higher than results for those assays commonly used in Europe and North America. The levels of SF are significantly elevated in patients before the onset of thrombosis, thus suggesting that the SF assay is useful not only for the diagnosis of thrombosis but also for diagnosing a prethrombotic state. Overall, elevated levels of FRMs indicate a high risk for thrombosis, and they are thus considered to be useful for the diagnosis of thrombosis.

REFERENCES

• 1 Linkins L A, Bates S M, Ginsberg J S, Kearon C. Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability.  J Thromb Haemost. 2004;  2 1256-1260
  CrossrefPubMedGoogle Scholar
• 2 Wada H. Disseminated intravascular coagulation.  Clin Chim Acta. 2004;  344 13-21
  CrossrefPubMedGoogle Scholar
• 3 Heit J A, Silverstein M D, Mohr D N et al.. The epidemiology of venous thromboembolism in the community.  Thromb Haemost. 2001;  86 452-463
  PubMedGoogle Scholar
• 4 Wells P S, Anderson D R, Rodger M et al.. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.  N Engl J Med. 2003;  349 1227-1235
  Google Scholar
• 5 Fedullo P F, Tapson V F. The evaluation of suspected pulmonary embolism.  N Engl J Med. 2003;  349 1247-1255
  CrossrefPubMedGoogle Scholar
• 6 Wada H, Wakita Y, Nakase T et al.. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun.  Thromb Haemost. 1995;  74 848-852
  PubMedGoogle Scholar
• 7 Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma.  Blood. 1996;  88 2109-2117
  PubMedGoogle Scholar
• 8 Kaneko T, Wada H, Onishi K et al.. Cutoff values of D-dimer and FDP in plasma for the diagnosis of thrombosis.  Vasc Dis Prevent. 2008;  , (in press)
  PubMedGoogle Scholar
• 9 Colman R W, Robby S J, Minna J D. Disseminated intravascular coagulation (DIC): an approach.  Am J Med. 1972;  52 679-689
  CrossrefPubMedGoogle Scholar
• 10 Taylor Jr F B, Toh C H, Hoots W K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - on behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH).  Thromb Haemost. 2001;  86 1327-1330
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Nieuwenhuizen W. A reference material for harmonization of D-dimer assays.  Thromb Haemost. 1997;  77 1031-1033
  PubMedGoogle Scholar
• 12 Dempfle C E, Zips S, Ergül H, Heene D L. The FACT study group: the fibrin assay comparison trial (FACT).  Thromb Haemost. 2001;  85 671-678
  PubMedGoogle Scholar
• 13 Ota S, Wada H, Nobori T et al.. Diagnosis of deep vein thrombosis by plasma-soluble fibrin or D-dimer.  Am J Hematol. 2005;  79 274-280
  CrossrefPubMedGoogle Scholar
• 14 Wada H, Kobayashi T, Abe Y et al.. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis.  J Thromb Haemost. 2006;  4 1253-1258
  CrossrefPubMedGoogle Scholar
• 15 Minamikawa K, Wada H, Wakita Y et al.. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism.  Thromb Haemost. 1994;  71 192-194
  PubMedGoogle Scholar
• 16 Yamada N, Wada H, Nakase T et al.. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis.  Blood Coagul Fibrinolysis. 1995;  6 627-633
  CrossrefPubMedGoogle Scholar
• 17 Wada H, Mori Y, Shimura M et al.. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.  Am J Hematol. 1998;  58 189-194
  CrossrefPubMedGoogle Scholar
• 18 Wada H, Mori Y, Kaneko T et al.. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia.  Am J Hematol. 1993;  44 112-116
  PubMedGoogle Scholar
• 19 Kline J A, Wells P S. Methodology for a rapid protocol to rule out pulmonary embolism in the emergency department.  Am J Emerg Med. 2003;  42 266-275
  PubMedGoogle Scholar
• 20 Dempfle C E. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.  Thromb Haemost. 1999;  82 673-683
  PubMedGoogle Scholar
• 21 Asakura H, Suga Y, Yoshida T et al.. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats.  Blood Coagul Fibrinolysis. 2003;  14 221-228
  CrossrefPubMedGoogle Scholar
• 22 Brass E P, Forman W B, Edwards R V, Lindan O. Fibrin formation; the role of fibrinogen-fibrin monomer complex.  Thromb Haemost. 1976;  36 37-48
  PubMedGoogle Scholar
• 23 Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma.  Clin Chim Acta. 2002;  318 25-32
  CrossrefPubMedGoogle Scholar
• 24 Suzuki A, Ebinuma H, Matsuo M, Miyazaki O, Yago H. The monoclonal antibody that recognize an epitope in the C-terminal region of the fibrinogen α-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.  Thromb Res. 2007;  121 377-385
  CrossrefPubMedGoogle Scholar
• 25 Wada H, Sase T, Matsumoto T et al.. Increased soluble fibrin in plasma from disseminated intravascular coagulation.  Clin Appl Thromb Hemost. 2003;  9 233-240
  CrossrefPubMedGoogle Scholar
• 26 Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review.  Blood Coagul Fibrinolysis. 1993;  4 93-96
  PubMedGoogle Scholar
• 27 Sumida Y, Wada H, Fuzii M et al.. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin- dependent-daibetes mellitus.  Blood Coagul Fibrinol. 1977;  8 303-307
  PubMedGoogle Scholar
• 28 Nielsen N E, Siegbahn A, Swahn E. Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics.  J Intern Med. 2000;  248 151-158
  CrossrefPubMedGoogle Scholar
• 29 Ieko M, Nakabayashi T, Tarumi T et al.. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.  Clin Chim Acta. 2007;  386 38-45
  CrossrefPubMedGoogle Scholar
• 30 Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients.  Semin Thromb Hemost. 1998;  24 293-297
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Watanabe R, Wada H, Yamamuro M et al.. Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation.  Clin Appl Thromb Hemost. 2003;  9 71-78
  CrossrefPubMedGoogle Scholar
• 32 Matsumoto T, Wada H, Nobori T et al.. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation.  Clin Appl Thromb Hemost. 2005;  11 391-400
  CrossrefPubMedGoogle Scholar

Prof. Hideo WadaM.D. Ph.D. 

Department of Laboratory Medicine, Mie University School of Medicine

2-174 Edobashi, Tsu-city, Mie-ken 514-8507, Japan

Email: wadahide@clin.medic.mie-u.ac.jp